Oricell Therapeutics Holdings Limited (Oricell), a biotech company working on new cancer treatments, has raised over US$110 million in a pre-IPO funding round. The round was led by investors like Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a global healthcare fund.
Other investors in the round include an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.
The company will use this funding to expand globally, speed up its clinical trials, improve its technology, and prepare for future milestones in the capital markets.
Dr. Huanfeng Yang, Chairman and CEO of Oricell Therapeutics, stated: “This financing is a testament to the global potential of our science and the dedication of our team. As we approach key inflection points in our clinical programs, our priority is clear: expedite the global development of our core assets and deepening our research into revolutionary technologies, including in vivo CAR-T and solid tumor CAR-T. We are committed to delivering transformative therapies that offer real hope to cancer patients worldwide, positioning Oricell as a dominant force in the global immunotherapy arena.”
Mr. Shan Fu, Managing Partner at Vivo Capital, commented: “While cell therapy is undoubtedly the future of oncology, solid tumors remain the industry’s toughest nut to crack. Oricell distinguishes itself not just through best-in-class clinical data for its GPC3 CAR-T, but also through a pragmatic and visionary roadmap for next-generation modalities like in vivo CAR-T. We have high conviction in their integrated ‘Platform and Pipeline’ strategy and believe they are poised to set the new standard of care in the field. Vivo Capital is eager to deploy our global network to accelerate Oricell’s expansion into international markets.”
Mr. William Hu, Managing Partner at Qiming Venture Partners, stated: “As an early investor that has stood with Oricell since the Pre-A round, we have witnessed every milestone of its journey—from technological exploration to pipeline realization, and from local innovation to global expansion. We look forward to Oricell leveraging breakthrough cell therapy solutions and stronger clinical data to define the next generation of cancer care, bringing hope to patients worldwide.”
Founded in 2015, Oricell is a biotechnology company that is developing new types of cell therapies to treat diseases like cancer and immune-related conditions.
The company uses its own technologies—Ori®Ab for discovering antibodies, Ori®Armoring to improve T-cells, and OnGo CMC for faster manufacturing. It is working on different treatments for both solid tumors and blood cancers, including a key drug candidate called OriCAR-017.
Read More- Chinese AI startup ShengShu Technology raises $293 million in round
